Low-Dose-Rate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavourable Risk Prostate Cancer: The Results of the ASCENDE-RT* Randomized Control Trial

William J Morris,Scott Tyldesley,Howard Pai,Ross Halperin, Sree Rodda,Graeme Duncan,Mira Keyes,Michael Mckenzie,Jeremy Hamm

Brachytherapy（2015）

引用 15|浏览21

暂无评分

摘要

Nadir+2 ng/mL 84.7% (5.6%) 71.1% (8.2%) O0.4 ng/mL 65.3% (6.4%) 59.2% (8.0%) O0.2 ng/mL 46.3% (7.6%) 38.8% (8.2%) LDR-PB boost Nadir+2 ng/mL 88.7% (4.8%) 86.2% (5.4%) O0.4 ng/mL 86.6% (5.2%) 84.3% (5.6%) O0.2 ng/mL 85.3% (5.2%) 82.1% (6.0%)

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要